A new study has found a blood test for cancer DNA could predict if a woman is responding to the new breast cancer
drug palbociclib, months earlier than current tests.
The proteasome is a novel downstream target for the anti ‐ cancer
drug palbociclib inhibiting proliferation by reduced proteasomal association with its inhibitor EMC29.
The breast cancer
drug palbociclib arrests cells in G1 phase by CDK4 / 6 inhibition, but also causes cellular senescence.
Not exact matches
And Onyx could receive milestone payments and royalties from
palbociclib, a
drug that Pfizer Inc. is studying as a breast cancer treatment.
While one
drug, MEK inhibitor, is usually used in advanced - stage melanoma, the other
drug, CDK4 / 6 inhibitor,
palbociclib, is currently FDA - approved for treatment of Estrogen Receptor - positive breast cancer patients.
The treatment arm received
palbociclib together with standard of care for this population, fulvestrant, a
drug that blocks the hormone receptor via a different mechanism than first - line therapies.
A new phase 3 study in some of the most difficult - to - treat patients, women with endocrine - resistant disease, showed that the newly approved
drug,
palbociclib, more than doubled the time to cancer recurrence for women with hormone - receptor (HR +) positive metastatic breast cancer.
The discovery that
palbociclib can activate proteasomal activity is important when considering potential
drug combinations to treat breast cancer.